董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Clinton H. Severson | 男 | Chairman of the Board and Chief Executive Officer | 69 | 443.21万美元 | 未持股 | 2017-08-31 |
| Richard J. Bastiani | 男 | Director | 74 | 28.05万美元 | 未持股 | 2017-08-31 |
| Henk J. Evenhuis | 男 | Director | 74 | 28.35万美元 | 未持股 | 2017-08-31 |
| Prithipal Singh | 男 | Director | 78 | 27.70万美元 | 未持股 | 2017-08-31 |
| Michael D. Casey | 男 | Director | 71 | 27.30万美元 | 未持股 | 2017-08-31 |
| Vernon E. Altman | 男 | Director | 72 | 27.80万美元 | 未持股 | 2017-08-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Craig M. Tockman | 男 | Vice President of Animal Health Sales and Marketing for North America | 57 | 182.82万美元 | 未持股 | 2017-08-31 |
| Ross Taylor | 男 | Chief Financial Officer, Vice President of Finance and Secretary | 54 | 178.66万美元 | 未持股 | 2017-08-31 |
| Clinton H. Severson | 男 | Chairman of the Board and Chief Executive Officer | 69 | 443.21万美元 | 未持股 | 2017-08-31 |
| Kenneth P. Aron | 男 | Chief Technology Officer | 64 | 182.83万美元 | 未持股 | 2017-08-31 |
| Donald P. Wood | 男 | President and Chief Operating Officer | 65 | 195.59万美元 | 未持股 | 2017-08-31 |
| Achim Henkel | 男 | Managing Director of Abaxis Europe GmbH | 59 | 204.48万美元 | 未持股 | 2017-08-31 |
董事简历
中英对照 | 中文 | 英文- Clinton H. Severson
-
Clinton H. Severson， 他1996年6月起担任本公司总裁，首席执行官兼公司董事，1998年5月被任命为董事会董事长，2011年6月，他曾任Response Biomedical生物医学公司董事会。2008年11月起everson的先生担任生物技术公司Trinity Biotech公司董事会（纳斯达克股票代码：TRIB）。2006年11月至2012年2月，曾任生物技术公司CytoCore公司（OTCBB：CYOE.OB）董事会成员。1989年2月至1996年5 月 曾担任私人持有的医疗诊断公司的MAST Immunosystems公司总裁兼首席执行官。他还是一家私人持有的公司的董事会成员。 他被选中是因为他深入了解本公司的经营业绩，财务状况和战略和现在所担任总裁兼首席执行官这样的职位，以及他在医疗诊断和服务的经验丰富的高级管理经验，能够效力于各种上市和私营公司的董事会。
Clinton H. Severson has served as our Chief Executive Officer and one of our directors since June 1996. He was appointed Chairman of the Board in May 1998. From June 1996 until April 2015 Mr. Severson also served as our President. From February 1989 to May 1996 Mr. Severson served as President and Chief Executive Officer of MAST Immunosystems, Inc., a privately-held medical diagnostic company. Since January 2015 Mr. Severson has served on the Board of Directors of Cutera. Since June 2011 Mr. Severson has served on the Board of Directors of Response Biomedical Corporation. From November 2008 to November 2016 Mr. Severson served on the Board of Directors of Trinity Biotech, a biotechnology company, prior to its acquisition. From November 2006 to February 2012 Mr. Severson served on the Board of Directors of CytoCore, Inc., a biotechnology company. - Clinton H. Severson， 他1996年6月起担任本公司总裁，首席执行官兼公司董事，1998年5月被任命为董事会董事长，2011年6月，他曾任Response Biomedical生物医学公司董事会。2008年11月起everson的先生担任生物技术公司Trinity Biotech公司董事会（纳斯达克股票代码：TRIB）。2006年11月至2012年2月，曾任生物技术公司CytoCore公司（OTCBB：CYOE.OB）董事会成员。1989年2月至1996年5 月 曾担任私人持有的医疗诊断公司的MAST Immunosystems公司总裁兼首席执行官。他还是一家私人持有的公司的董事会成员。 他被选中是因为他深入了解本公司的经营业绩，财务状况和战略和现在所担任总裁兼首席执行官这样的职位，以及他在医疗诊断和服务的经验丰富的高级管理经验，能够效力于各种上市和私营公司的董事会。
- Clinton H. Severson has served as our Chief Executive Officer and one of our directors since June 1996. He was appointed Chairman of the Board in May 1998. From June 1996 until April 2015 Mr. Severson also served as our President. From February 1989 to May 1996 Mr. Severson served as President and Chief Executive Officer of MAST Immunosystems, Inc., a privately-held medical diagnostic company. Since January 2015 Mr. Severson has served on the Board of Directors of Cutera. Since June 2011 Mr. Severson has served on the Board of Directors of Response Biomedical Corporation. From November 2008 to November 2016 Mr. Severson served on the Board of Directors of Trinity Biotech, a biotechnology company, prior to its acquisition. From November 2006 to February 2012 Mr. Severson served on the Board of Directors of CytoCore, Inc., a biotechnology company.
- Richard J. Bastiani
-
Richard J. Bastiani， 他于1995年9月加入董事会，现已退休。2007年至2011 年曾任Response Biomedical公司董事长（加拿大风险资本交易所代码：RBM） 1998年至2005 曾任ID生物医学公司的董事长。（纳斯达克股票代码：IDBE），之后，1996年10月，他被任命为ID生物医学公司董事。1995年9月至1998年9月，他曾任生物技术公司Dendreon公司总裁（纳斯达克交易代码：DNDN）。1971年到1995年他曾在Syva公司担任众多职务，包括总裁（1991年直到Syva公司于1995年被赫斯特的子公司收购）。他还是两家私人持有的公司董事会成员。 他被任命为董事会成员，是因为他在生物技术公司丰富的领导经验和对业务，战略和管理团队的深入了解，以及他作为薪酬委员会主席和出任上市及私有公司董事的相关 工作经验。
Richard J. Bastiani has served as a member of the board of directors and our Chairman since the Merger. He has previously served as a member of the board of directors of C3J from 2013 until the consummation of the Merger. Dr. Bastiani is currently retired. He has over 40 years of industry experience and has served on the boards of 14 biotechnology and life science companies throughout his career, including as a director of BioNex Solutions, Inc., a privately-held company that develops and manufactures systems for laboratory automation and liquid handling, since 2014. From 1995 through 2018 he served as a member of the board of directors of Abaxis, Inc., a formerly public diagnostic company providing point of care, automated blood analysis systems and single test products for human and veterinary markets that was acquired by Zoetis Inc. in 2018 for approximately $2.0 billion. From 1995 to 1998 Dr. Bastiani was President of Dendreon, a biotechnology company dedicated to providing innovative cell therapies for cancer. From 1970 until 1995 Dr. Bastiani held a number of positions with Syva Company, a diagnostic company, including as President from 1991 until Syva Company was acquired by a subsidiary of Hoechst AG of Germany in 1995. From 2007 to 2011 Dr. Bastiani served as chairman of the board of directors of Response Biomedical Corp. In 1996 Dr. Bastiani was appointed to the board of directors of ID Biomedical Corporation, and he served as the chairman of the board of directors from 1998 until the company’s 2005 acquisition by GlaxoSmithKline. Dr. Bastiani also served as co-founder and a director of DiscoveRx, a privately held company developing and selling high-throughput screening, protein profile and cell pathway assays and services, and on the board of Pathwork Diagnostics, a privately held molecular diagnostic company focused on cancer diagnostics using proprietary genomic profiling and informatics. Dr. Bastiani also serves on the Board of Fellows of Santa Clara University. He received his Ph.D. in Chemistry from Michigan State University in 1970 his M.S. in Chemistry from California State University in 1967 and his B.S. in Chemistry from Santa Clara University in 1964. - Richard J. Bastiani， 他于1995年9月加入董事会，现已退休。2007年至2011 年曾任Response Biomedical公司董事长（加拿大风险资本交易所代码：RBM） 1998年至2005 曾任ID生物医学公司的董事长。（纳斯达克股票代码：IDBE），之后，1996年10月，他被任命为ID生物医学公司董事。1995年9月至1998年9月，他曾任生物技术公司Dendreon公司总裁（纳斯达克交易代码：DNDN）。1971年到1995年他曾在Syva公司担任众多职务，包括总裁（1991年直到Syva公司于1995年被赫斯特的子公司收购）。他还是两家私人持有的公司董事会成员。 他被任命为董事会成员，是因为他在生物技术公司丰富的领导经验和对业务，战略和管理团队的深入了解，以及他作为薪酬委员会主席和出任上市及私有公司董事的相关 工作经验。
- Richard J. Bastiani has served as a member of the board of directors and our Chairman since the Merger. He has previously served as a member of the board of directors of C3J from 2013 until the consummation of the Merger. Dr. Bastiani is currently retired. He has over 40 years of industry experience and has served on the boards of 14 biotechnology and life science companies throughout his career, including as a director of BioNex Solutions, Inc., a privately-held company that develops and manufactures systems for laboratory automation and liquid handling, since 2014. From 1995 through 2018 he served as a member of the board of directors of Abaxis, Inc., a formerly public diagnostic company providing point of care, automated blood analysis systems and single test products for human and veterinary markets that was acquired by Zoetis Inc. in 2018 for approximately $2.0 billion. From 1995 to 1998 Dr. Bastiani was President of Dendreon, a biotechnology company dedicated to providing innovative cell therapies for cancer. From 1970 until 1995 Dr. Bastiani held a number of positions with Syva Company, a diagnostic company, including as President from 1991 until Syva Company was acquired by a subsidiary of Hoechst AG of Germany in 1995. From 2007 to 2011 Dr. Bastiani served as chairman of the board of directors of Response Biomedical Corp. In 1996 Dr. Bastiani was appointed to the board of directors of ID Biomedical Corporation, and he served as the chairman of the board of directors from 1998 until the company’s 2005 acquisition by GlaxoSmithKline. Dr. Bastiani also served as co-founder and a director of DiscoveRx, a privately held company developing and selling high-throughput screening, protein profile and cell pathway assays and services, and on the board of Pathwork Diagnostics, a privately held molecular diagnostic company focused on cancer diagnostics using proprietary genomic profiling and informatics. Dr. Bastiani also serves on the Board of Fellows of Santa Clara University. He received his Ph.D. in Chemistry from Michigan State University in 1970 his M.S. in Chemistry from California State University in 1967 and his B.S. in Chemistry from Santa Clara University in 1964.
- Henk J. Evenhuis
-
Henk J. Evenhuis， 他于2002年11月加入董事会，现已退休。1993年至2008年，他曾担任半导体设备制造商Credence Systems公司（纳斯达克代码：CMOS）董事会成员。1999年10月至2002年10月，他曾经担任面向金融服务，保险和医疗保健行业提供软件产品的全球供应商Fair Isaac公司的执行副总裁兼首席财务官（纽约证券交易所代码：FIC）。1987年到1998年，他曾任半导体设备制造商Lam Research公司总裁兼首席财务官。（纳斯达克股票代码：LRCX）。 他被选任为本公司董事，是因为他的金融专业知识和在全球性技术公司担任首席财务官这样的高层领导的工作经验以及他务于多家上市公司的董事会的经验这位他出任审核委员会主席打下了坚实的基础。
Henk J. Evenhuis joined the Board in November 2002. Mr. Evenhuis is currently retired. Mr. Evenhuis served as Executive Vice President and Chief Financial Officer of Fair Isaac Corporation, an analytic software company, from October 1999 to October 2002. From 1987 to 1998 he was Executive Vice President and Chief Financial Officer of Lam Research Corporation, a semiconductor equipment manufacturer. He served on the Board of Directors of Credence Systems Corporation from 1993 to 2008. - Henk J. Evenhuis， 他于2002年11月加入董事会，现已退休。1993年至2008年，他曾担任半导体设备制造商Credence Systems公司（纳斯达克代码：CMOS）董事会成员。1999年10月至2002年10月，他曾经担任面向金融服务，保险和医疗保健行业提供软件产品的全球供应商Fair Isaac公司的执行副总裁兼首席财务官（纽约证券交易所代码：FIC）。1987年到1998年，他曾任半导体设备制造商Lam Research公司总裁兼首席财务官。（纳斯达克股票代码：LRCX）。 他被选任为本公司董事，是因为他的金融专业知识和在全球性技术公司担任首席财务官这样的高层领导的工作经验以及他务于多家上市公司的董事会的经验这位他出任审核委员会主席打下了坚实的基础。
- Henk J. Evenhuis joined the Board in November 2002. Mr. Evenhuis is currently retired. Mr. Evenhuis served as Executive Vice President and Chief Financial Officer of Fair Isaac Corporation, an analytic software company, from October 1999 to October 2002. From 1987 to 1998 he was Executive Vice President and Chief Financial Officer of Lam Research Corporation, a semiconductor equipment manufacturer. He served on the Board of Directors of Credence Systems Corporation from 1993 to 2008.
- Prithipal Singh
-
Prithipal Singh， 他于1992年6月出任董事，退休之前，1988年至1998年，他曾任ChemTrak公司创始人兼董事长兼首席执行官。在此之前，1985年至1988年，他曾任Idetec公司执行副总裁，1977年至1985年，他曾任Syva公司副总裁。他被选任务董事是因为他之前在生物技术公司担任前行政领导和管理职位的经历以及他的洞察力和工作经验。
Prithipal Singh, Ph.D.joined the Board in June 1992. Dr. Singh is currently retired. Prior to retiring, Dr. Singh was the Founder, Chairman and Chief Executive Officer of ChemTrak Inc., a manufacturer of medical diagnostic equipment, from 1988 to 1998. Dr. Singh was an Executive Vice President of Idetec Corporation, an animal health care company, from 1985 to 1988 and a Vice President of Syva Corporation, a diagnostic company, from 1977 to 1985. - Prithipal Singh， 他于1992年6月出任董事，退休之前，1988年至1998年，他曾任ChemTrak公司创始人兼董事长兼首席执行官。在此之前，1985年至1988年，他曾任Idetec公司执行副总裁，1977年至1985年，他曾任Syva公司副总裁。他被选任务董事是因为他之前在生物技术公司担任前行政领导和管理职位的经历以及他的洞察力和工作经验。
- Prithipal Singh, Ph.D.joined the Board in June 1992. Dr. Singh is currently retired. Prior to retiring, Dr. Singh was the Founder, Chairman and Chief Executive Officer of ChemTrak Inc., a manufacturer of medical diagnostic equipment, from 1988 to 1998. Dr. Singh was an Executive Vice President of Idetec Corporation, an animal health care company, from 1985 to 1988 and a Vice President of Syva Corporation, a diagnostic company, from 1977 to 1985.
- Michael D. Casey
-
Michael D. Casey于2010年10月加入董事会，现已退休。从1997年9月至2002年2月，他担任Matrix药业有限公司的董事长、总裁、首席执行官和董事。从1995年11月至1997年9月，他是施恩制药公司（纽约证券交易所代码：SHP）的执行副总裁。 1996年12月，他被任命为施恩药品的零售和特种产品部门的部长。从1993年6月至1995年11月，他担任基因治疗公司的总裁兼首席运营官。从1989年到1993年6月，他是麦克尼尔制药公司（强生公司旗下的一个单位）的总裁。1985年至1989年，担任Ortho制药公司（强生公司的子公司）负责销售和市场营销的副总裁。自2002年起，担任Celgene公司（纳斯达克股票代码：CELG）的董事。自2004年起，担任Durect公司（纳斯达克股票代码：DRRX）的董事。从2006年至2010年，担任AVI生物制药公司的董事会成员；从2002年至2010年，担任阿洛斯治疗公司（纳斯达克股票代码：ALTH）的董事。自2001到2007年担任Cholestech公司董事。从2004至2007年担任OrthoLogic公司（纳斯达克股票代码：OLGC）的董事。从2002年到2004年担任SICOR （纳斯达克股票代码：SCRI）的董事。从2001年到2005年担任骨保健国际公司（纳斯达克股票代码：BCII）的董事。他成为公司董事是因为丰富的行业知识和经验，包括运营、领导和董事会经验，这是他在制药/生物工程公司行政职位中获得的。
Michael D. Casey has served as one of the company's Directors since August 2002 and has been our independent Lead Director since June 2007 the Chairman of the Nominating Committee and a member of the Executive Committee since December 2006 and a member of the Management Compensation and Development Committee referred to as the Compensation Committee since April 2006. Mr. Casey was a member of the Audit Committee from August 2002 through December 2006. From September 1997 to February 2002 Mr. Casey served as the Chairman, President, Chief Executive Officer and a director of Matrix Pharmaceutical, Inc. From November 1995 to September 1997 Mr. Casey was Executive Vice President at Schein Pharmaceutical, Inc.December 1996 he was appointed President of the retail and specialty products division of Schein Pharmaceutical, Inc. From June 1993 to November 1995 he served as President and Chief Operating Officer of Genetic Therapy, Inc. Mr. Casey was President of McNeil Pharmaceutical (a unit of Johnson & Johnson) from 1989 to June 1993 and Vice President, Sales and Marketing for Ortho Pharmaceutical Corp. (a subsidiary of Johnson & Johnson) from 1985 to 1989. Mr. Casey is also a Director of Abaxis Inc. (and a member of the Compensation Committee). Mr. Casey served as a Director of Allos Therapeutics, Inc. through January 2010 AVI BioPharma (now Sarepta Therapeutics, Inc.) through June 2010 and Durect Corporation through December 2013. - Michael D. Casey于2010年10月加入董事会，现已退休。从1997年9月至2002年2月，他担任Matrix药业有限公司的董事长、总裁、首席执行官和董事。从1995年11月至1997年9月，他是施恩制药公司（纽约证券交易所代码：SHP）的执行副总裁。 1996年12月，他被任命为施恩药品的零售和特种产品部门的部长。从1993年6月至1995年11月，他担任基因治疗公司的总裁兼首席运营官。从1989年到1993年6月，他是麦克尼尔制药公司（强生公司旗下的一个单位）的总裁。1985年至1989年，担任Ortho制药公司（强生公司的子公司）负责销售和市场营销的副总裁。自2002年起，担任Celgene公司（纳斯达克股票代码：CELG）的董事。自2004年起，担任Durect公司（纳斯达克股票代码：DRRX）的董事。从2006年至2010年，担任AVI生物制药公司的董事会成员；从2002年至2010年，担任阿洛斯治疗公司（纳斯达克股票代码：ALTH）的董事。自2001到2007年担任Cholestech公司董事。从2004至2007年担任OrthoLogic公司（纳斯达克股票代码：OLGC）的董事。从2002年到2004年担任SICOR （纳斯达克股票代码：SCRI）的董事。从2001年到2005年担任骨保健国际公司（纳斯达克股票代码：BCII）的董事。他成为公司董事是因为丰富的行业知识和经验，包括运营、领导和董事会经验，这是他在制药/生物工程公司行政职位中获得的。
- Michael D. Casey has served as one of the company's Directors since August 2002 and has been our independent Lead Director since June 2007 the Chairman of the Nominating Committee and a member of the Executive Committee since December 2006 and a member of the Management Compensation and Development Committee referred to as the Compensation Committee since April 2006. Mr. Casey was a member of the Audit Committee from August 2002 through December 2006. From September 1997 to February 2002 Mr. Casey served as the Chairman, President, Chief Executive Officer and a director of Matrix Pharmaceutical, Inc. From November 1995 to September 1997 Mr. Casey was Executive Vice President at Schein Pharmaceutical, Inc.December 1996 he was appointed President of the retail and specialty products division of Schein Pharmaceutical, Inc. From June 1993 to November 1995 he served as President and Chief Operating Officer of Genetic Therapy, Inc. Mr. Casey was President of McNeil Pharmaceutical (a unit of Johnson & Johnson) from 1989 to June 1993 and Vice President, Sales and Marketing for Ortho Pharmaceutical Corp. (a subsidiary of Johnson & Johnson) from 1985 to 1989. Mr. Casey is also a Director of Abaxis Inc. (and a member of the Compensation Committee). Mr. Casey served as a Director of Allos Therapeutics, Inc. through January 2010 AVI BioPharma (now Sarepta Therapeutics, Inc.) through June 2010 and Durect Corporation through December 2013.
- Vernon E. Altman
-
Vernon E. Altman， 他于2011年4月加入本公司董事会。他于1973年加入全球性商业咨询公司贝恩公司创办集团并出任高级顾问，现任Vobile公司的董事长，该公司专注于内容保护和商业化的媒体公司和其他数字媒体的利益相关者。他曾供职于Napster公司董事会。他被任命为公司董事是因为他在许多不同的行业领域，包括营运，行政领导和董事会的工作经验。
Vernon E. Altman joined the Board in April 2011 and has served as our lead independent director since April 2014. Mr. Altman joined the founding group to start Bain & Company, a global business consulting firm, in 1973 and is currently Senior Advisor of Bain & Company. Mr. Altman is Chairman of the Board of Directors of Vobile, Inc. He also served on the Board of Directors of Napster, Inc. prior to its acquisition. - Vernon E. Altman， 他于2011年4月加入本公司董事会。他于1973年加入全球性商业咨询公司贝恩公司创办集团并出任高级顾问，现任Vobile公司的董事长，该公司专注于内容保护和商业化的媒体公司和其他数字媒体的利益相关者。他曾供职于Napster公司董事会。他被任命为公司董事是因为他在许多不同的行业领域，包括营运，行政领导和董事会的工作经验。
- Vernon E. Altman joined the Board in April 2011 and has served as our lead independent director since April 2014. Mr. Altman joined the founding group to start Bain & Company, a global business consulting firm, in 1973 and is currently Senior Advisor of Bain & Company. Mr. Altman is Chairman of the Board of Directors of Vobile, Inc. He also served on the Board of Directors of Napster, Inc. prior to its acquisition.
高管简历
中英对照 | 中文 | 英文- Craig M. Tockman
Craig M. Tockman，2014年4月以来。他担任我们北美动物卫生销售和营销副总裁。2006年6月他加入我们担任专业服务董事并在2013年10月被提升为野外作业董事。从2003年到2006年，他担任Abaxis的顾问委员会职务。2003年他以创始成员加入。
Craig M. Tockman, DVM has served as our Vice President of Animal Health Sales and Marketing for North America since April 2014. Dr. Tockman joined in June 2006 as Director of Professional Services and was promoted to Director of Field Operations in October 2013. From 2003 to 2006 Dr. Tockman served on Abaxis’ Advisory Board since he joined in 2003 as a founding member.- Craig M. Tockman，2014年4月以来。他担任我们北美动物卫生销售和营销副总裁。2006年6月他加入我们担任专业服务董事并在2013年10月被提升为野外作业董事。从2003年到2006年，他担任Abaxis的顾问委员会职务。2003年他以创始成员加入。
- Craig M. Tockman, DVM has served as our Vice President of Animal Health Sales and Marketing for North America since April 2014. Dr. Tockman joined in June 2006 as Director of Professional Services and was promoted to Director of Field Operations in October 2013. From 2003 to 2006 Dr. Tockman served on Abaxis’ Advisory Board since he joined in 2003 as a founding member.
- Ross Taylor
Ross Taylor，他曾一直担任BillionToOne，Inc.首席财务官、财务副总裁和秘书（2015年8月以来）。他于2014年10月加入公司，并担任副总裁，负责业务发展和投资者关系。从2005年到2014年，他曾担任CL King & Associates公司（投资银行公司）的高级副总裁、股票研究分析师。
Ross Taylor has served as Chief Financial Officer since January 2024. Prior to joining BillionToOne, Mr. Taylor was Chief Financial Officer for Codexis, Inc., a publicly traded enzyme engineering company, from 2019 to February 2023. Previoly, he served as Chief Financial Officer of Abaxis, Inc., a publicly traded medical technology company, acquired by Zoetis for $2.0 billion. At Abaxis, he first held the role of Vice President of Biness Development & Investor Relations from 2014 to 2015, before being appointed CFO from Augt 2015 through the company's successful acquisition in July 2018. Early in his career, Mr. Taylor spent more than a decade as an equity research analyst at leading Wall Street firms including CL King & Associates, UBS, Smith Barney, and CJ Lawrence, providing deep expertise in capital markets and strategic financial planning. Mr. Taylor holds an MBA from Columbia Biness School and a B.A. in economics from Duke University.- Ross Taylor，他曾一直担任BillionToOne，Inc.首席财务官、财务副总裁和秘书（2015年8月以来）。他于2014年10月加入公司，并担任副总裁，负责业务发展和投资者关系。从2005年到2014年，他曾担任CL King & Associates公司（投资银行公司）的高级副总裁、股票研究分析师。
- Ross Taylor has served as Chief Financial Officer since January 2024. Prior to joining BillionToOne, Mr. Taylor was Chief Financial Officer for Codexis, Inc., a publicly traded enzyme engineering company, from 2019 to February 2023. Previoly, he served as Chief Financial Officer of Abaxis, Inc., a publicly traded medical technology company, acquired by Zoetis for $2.0 billion. At Abaxis, he first held the role of Vice President of Biness Development & Investor Relations from 2014 to 2015, before being appointed CFO from Augt 2015 through the company's successful acquisition in July 2018. Early in his career, Mr. Taylor spent more than a decade as an equity research analyst at leading Wall Street firms including CL King & Associates, UBS, Smith Barney, and CJ Lawrence, providing deep expertise in capital markets and strategic financial planning. Mr. Taylor holds an MBA from Columbia Biness School and a B.A. in economics from Duke University.
- Clinton H. Severson
Clinton H. Severson， 他1996年6月起担任本公司总裁，首席执行官兼公司董事，1998年5月被任命为董事会董事长，2011年6月，他曾任Response Biomedical生物医学公司董事会。2008年11月起everson的先生担任生物技术公司Trinity Biotech公司董事会（纳斯达克股票代码：TRIB）。2006年11月至2012年2月，曾任生物技术公司CytoCore公司（OTCBB：CYOE.OB）董事会成员。1989年2月至1996年5 月 曾担任私人持有的医疗诊断公司的MAST Immunosystems公司总裁兼首席执行官。他还是一家私人持有的公司的董事会成员。 他被选中是因为他深入了解本公司的经营业绩，财务状况和战略和现在所担任总裁兼首席执行官这样的职位，以及他在医疗诊断和服务的经验丰富的高级管理经验，能够效力于各种上市和私营公司的董事会。
Clinton H. Severson has served as our Chief Executive Officer and one of our directors since June 1996. He was appointed Chairman of the Board in May 1998. From June 1996 until April 2015 Mr. Severson also served as our President. From February 1989 to May 1996 Mr. Severson served as President and Chief Executive Officer of MAST Immunosystems, Inc., a privately-held medical diagnostic company. Since January 2015 Mr. Severson has served on the Board of Directors of Cutera. Since June 2011 Mr. Severson has served on the Board of Directors of Response Biomedical Corporation. From November 2008 to November 2016 Mr. Severson served on the Board of Directors of Trinity Biotech, a biotechnology company, prior to its acquisition. From November 2006 to February 2012 Mr. Severson served on the Board of Directors of CytoCore, Inc., a biotechnology company.- Clinton H. Severson， 他1996年6月起担任本公司总裁，首席执行官兼公司董事，1998年5月被任命为董事会董事长，2011年6月，他曾任Response Biomedical生物医学公司董事会。2008年11月起everson的先生担任生物技术公司Trinity Biotech公司董事会（纳斯达克股票代码：TRIB）。2006年11月至2012年2月，曾任生物技术公司CytoCore公司（OTCBB：CYOE.OB）董事会成员。1989年2月至1996年5 月 曾担任私人持有的医疗诊断公司的MAST Immunosystems公司总裁兼首席执行官。他还是一家私人持有的公司的董事会成员。 他被选中是因为他深入了解本公司的经营业绩，财务状况和战略和现在所担任总裁兼首席执行官这样的职位，以及他在医疗诊断和服务的经验丰富的高级管理经验，能够效力于各种上市和私营公司的董事会。
- Clinton H. Severson has served as our Chief Executive Officer and one of our directors since June 1996. He was appointed Chairman of the Board in May 1998. From June 1996 until April 2015 Mr. Severson also served as our President. From February 1989 to May 1996 Mr. Severson served as President and Chief Executive Officer of MAST Immunosystems, Inc., a privately-held medical diagnostic company. Since January 2015 Mr. Severson has served on the Board of Directors of Cutera. Since June 2011 Mr. Severson has served on the Board of Directors of Response Biomedical Corporation. From November 2008 to November 2016 Mr. Severson served on the Board of Directors of Trinity Biotech, a biotechnology company, prior to its acquisition. From November 2006 to February 2012 Mr. Severson served on the Board of Directors of CytoCore, Inc., a biotechnology company.
- Kenneth P. Aron
Kenneth P. Aron， 他自2008年4月起一直担任首席技术官。他于2000年2月加盟本公司，担任研究及发展部副总裁。1998年4月至1999年11月，他曾任基因组信息公司Incyte制药公司（纳斯达克代码：INCY）。1996年4月至1998年4月，他曾任基于激光的心脏外科产品制造商Cardiogenesis公司（纳斯达克股票代码：CGCP）发展和工程部副总裁。
Kenneth P. Aron, Ph.D.has served as our Chief Technology Officer since April 2008. Dr. Aron joined us in February 2000 as Vice President of Research and Development. From April 1998 to November 1999 Dr. Aron was Vice President of Engineering and Technology of Incyte Pharmaceuticals, a genomic information company. From April 1996 to April 1998 Dr. Aron was Vice President of Research, Development and Engineering for Cardiogenesis Corporation, a manufacturer of laser-based cardiology surgical products.- Kenneth P. Aron， 他自2008年4月起一直担任首席技术官。他于2000年2月加盟本公司，担任研究及发展部副总裁。1998年4月至1999年11月，他曾任基因组信息公司Incyte制药公司（纳斯达克代码：INCY）。1996年4月至1998年4月，他曾任基于激光的心脏外科产品制造商Cardiogenesis公司（纳斯达克股票代码：CGCP）发展和工程部副总裁。
- Kenneth P. Aron, Ph.D.has served as our Chief Technology Officer since April 2008. Dr. Aron joined us in February 2000 as Vice President of Research and Development. From April 1998 to November 1999 Dr. Aron was Vice President of Engineering and Technology of Incyte Pharmaceuticals, a genomic information company. From April 1996 to April 1998 Dr. Aron was Vice President of Research, Development and Engineering for Cardiogenesis Corporation, a manufacturer of laser-based cardiology surgical products.
- Donald P. Wood
Donald P. Wood, j 他于2009年4月一直担任首席营运官，于2007年10月加盟本公司并出任运营副总裁从2003年4月至2007年9月，他曾效力于医疗产品制造公司Cholestech公司运营部副总裁，后于2007年9月被英维利斯医疗诊断集团收购。2001年7月至2003年3月，他曾经担任医疗点诊断护理的制造和营销商Quidel公司骨骼健康部副总裁，并负责骨骼健康产品运营，设备的研究和开发，以及销售和市场营销。1999年8月至2001年7月，他曾任超声操作部副总裁。1998年7月至1999年8月，Quidel被Metra Biosystems公司收购之前，加盟Quidel公司之前，他曾任Metra Biosystems公司超声操作部总监。
Donald P. Wood has served as our President and Chief Operating Officer since April 2015. Mr. Wood joined us in October 2007 as Vice President of Operations, served as Chief Operations Officer from April 2009 to April 2014 and served as Chief Operating Officer from April 2014 to April 2015. From April 2003 to September 2007 Mr. Wood was the Vice President of Operations of Cholestech Corporation, a medical products manufacturing company that was subsequently acquired by Inverness Medical Innovations, Inc. in September 2007. From July 2001 to March 2003 Mr. Wood served as Vice President of Bone Health, a business unit of Quidel Corporation, a manufacturing and marketer of point-of-care diagnostics, and was responsible for Bone Health Product Operations, Device Research and Development, and Sales and Marketing. He also served as Quidel’s Vice President of Ultrasound Operations from August 1999 to July 2001. From July 1998 to August 1999 Mr. Wood was the Director of Ultrasound Operations for Metra Biosystems Inc., a developer and manufacturing company of point-of-care products for osteoporosis, prior to Quidel’s acquisition of Metra Biosystems Inc.- Donald P. Wood, j 他于2009年4月一直担任首席营运官，于2007年10月加盟本公司并出任运营副总裁从2003年4月至2007年9月，他曾效力于医疗产品制造公司Cholestech公司运营部副总裁，后于2007年9月被英维利斯医疗诊断集团收购。2001年7月至2003年3月，他曾经担任医疗点诊断护理的制造和营销商Quidel公司骨骼健康部副总裁，并负责骨骼健康产品运营，设备的研究和开发，以及销售和市场营销。1999年8月至2001年7月，他曾任超声操作部副总裁。1998年7月至1999年8月，Quidel被Metra Biosystems公司收购之前，加盟Quidel公司之前，他曾任Metra Biosystems公司超声操作部总监。
- Donald P. Wood has served as our President and Chief Operating Officer since April 2015. Mr. Wood joined us in October 2007 as Vice President of Operations, served as Chief Operations Officer from April 2009 to April 2014 and served as Chief Operating Officer from April 2014 to April 2015. From April 2003 to September 2007 Mr. Wood was the Vice President of Operations of Cholestech Corporation, a medical products manufacturing company that was subsequently acquired by Inverness Medical Innovations, Inc. in September 2007. From July 2001 to March 2003 Mr. Wood served as Vice President of Bone Health, a business unit of Quidel Corporation, a manufacturing and marketer of point-of-care diagnostics, and was responsible for Bone Health Product Operations, Device Research and Development, and Sales and Marketing. He also served as Quidel’s Vice President of Ultrasound Operations from August 1999 to July 2001. From July 1998 to August 1999 Mr. Wood was the Director of Ultrasound Operations for Metra Biosystems Inc., a developer and manufacturing company of point-of-care products for osteoporosis, prior to Quidel’s acquisition of Metra Biosystems Inc.
- Achim Henkel
Achim Henkel， 他自2008年Abaxis Europe GmbH（本公司子公司）起一直担任该公司常务董事。他于1998年1月加盟本公司，担任顾问，以建立一个欧洲分销网络。2000年1月至2008年6月，他曾任销售和营销部经理，负责欧洲，中东和非洲地区的业务。1996年10月至1997年12月，他曾经自雇于几家顾问公司。1988年1月至1996年9月，他曾在Syva Diagnostics Germany公司担任众多职务，包括1991年直至Syva Diagnostics Germany公司在1995年收购了一家赫斯特集团的子公司，他一直担任全国销售经理。1982年至1987年，他曾任德国制药公司赫斯特公司区域销售经理。
Achim Henkel has served as the Managing Director of our subsidiary, Abaxis Europe GmbH, since its incorporation in 2008. From January 2000 to June 2008 Mr. Henkel served as our Sales and Marketing Manager for Europe, the Middle East and Africa. Starting in October 2014 Mr. Henkel has also served as our Sales and Marketing Manager for Asia. From January 1998 to December 2000 Mr. Henkel served as a consultant to Abaxis.- Achim Henkel， 他自2008年Abaxis Europe GmbH（本公司子公司）起一直担任该公司常务董事。他于1998年1月加盟本公司，担任顾问，以建立一个欧洲分销网络。2000年1月至2008年6月，他曾任销售和营销部经理，负责欧洲，中东和非洲地区的业务。1996年10月至1997年12月，他曾经自雇于几家顾问公司。1988年1月至1996年9月，他曾在Syva Diagnostics Germany公司担任众多职务，包括1991年直至Syva Diagnostics Germany公司在1995年收购了一家赫斯特集团的子公司，他一直担任全国销售经理。1982年至1987年，他曾任德国制药公司赫斯特公司区域销售经理。
- Achim Henkel has served as the Managing Director of our subsidiary, Abaxis Europe GmbH, since its incorporation in 2008. From January 2000 to June 2008 Mr. Henkel served as our Sales and Marketing Manager for Europe, the Middle East and Africa. Starting in October 2014 Mr. Henkel has also served as our Sales and Marketing Manager for Asia. From January 1998 to December 2000 Mr. Henkel served as a consultant to Abaxis.